At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
AQ001S 0.125 mg/ml +1 moredrug
Likely dose
AQ001S 0.125 mg/mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Active-controlled, Randomized, Open Label, Single-center, Multiple Dose, Crossover Clinical Trial to Assess the Efficacy, Safety and PK of AQ001S Compared to a Budesonide Inhalation Suspension in Adults With Mild Asthma
In Brief
A Phase 2 clinical trial evaluating AQ001S 0.125 mg/ml and Budesonide 0.125 mg/ml inhalation suspension for Asthma. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This is a prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the efficacy, safety and pharmacokinetics of AQ001S compared to a budesonide inhalation suspension (comparator) in adults with mild asthma. Both treatments will be administered by nebulization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJul 2021
Primary CompletionDec 2022
Study CompletionJan 2023
TodayJul 2026
First PostedJun 21, 2021
Enrollment StartJul 23, 2021
Primary CompletionDec 31, 2022
Study CompletionJan 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.0 years ago
Interventions
AQ001S 0.125 mg/mldrug
administered by nebulization once daily
Budesonide 0.125 mg/ml inhalation suspensiondrug
administered by nebulization once daily